Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
Glenmark received a warning letter and initiated a recall due to a subpar investigation into a tablet manufacturing glitch, highlighting FDA scrutiny of cGMP compliance and investigation adequacy.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Generic/ANDA manufacturers, API & contract manufacturers, branded drug makers should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; FDA inspections may occur at any time.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA issued a warning letter to Glenmark for inadequate investigation of a manufacturing deviation, leading to a recall. This signals increased enforcement on root cause analysis and corrective actions.
Who it affects
Generic/ANDA manufacturers, API & contract manufacturers, branded drug makers
What you must do
Review and strengthen deviation investigation procedures to ensure thorough root cause analysis and timely corrective actions.
Deadline
Immediately; FDA inspections may occur at any time.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- GLP‑1 Compliance: FDA Targets Telehealth Marketing in 30 New Warning Letters - JD Supra
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines
- Governor signs bill requiring informed consent for nursing home patients for prescription of antipsychotic drugs - Oklahoma State Senate (.gov)